High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors

•A large dataset of patients across different types of PD-(L)1 inhibitors and various solid tumor indications were evaluated.•Patients with BMI ≥30 kg/m2 are at an increased risk of developing an irAE across cancer types and study drugs.•Patients with an autoimmune disorder are also at an increased risk of developing an irAE across cancer types and study drugs. BackgroundTreatment with anti-PD-(L)1 antibodies, approved for several oncology...